VIPIN RAMPRASAD LOHIYA, M.D.

Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Administration of chemotherapy into vein, 1 hour or less

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

New patient office or other outpatient visit, 45-59 minutes

Administration of chemotherapy into vein using push technique

Established patient office or other outpatient visit, 40-54 minutes

Established patient office or other outpatient visit, 30-39 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of additional new drug or substance into vein using push technique

Infusion into a vein for hydration, 31-60 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Established patient office or other outpatient visit, 20-29 minutes

Administration of chemotherapy into vein, each additional hour

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Injection, pembrolizumab, 1 mg

Infusion into a vein for hydration, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Influenza vaccine split virus, preservative free

Injection of additional new drug or substance into vein

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Cyclophosphamide, 100 mg

Injection, ferric derisomaltose, 10 mg

Injection of drug or substance under skin or into muscle

Administration of influenza virus vaccine

Injection, denosumab, 1 mg

Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count

Urinalysis, manual test

Injection, carboplatin, 50 mg

Injection, leucovorin calcium, per 50 mg

Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg

Injection, irinotecan, 20 mg

Injection, palonosetron hcl, 25 mcg

Infusion, normal saline solution , 1000 cc

Injection, fluorouracil, 500 mg

Unclassified drugs

Injection, diphenhydramine hcl, up to 50 mg

Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram

Injection, granisetron hydrochloride, 100 mcg

Injection, atropine sulfate, 0.01 mg

Injection, oxaliplatin, 0.5 mg

Injection, dexamethasone sodium phosphate, 1 mg